Abstract Details

Title Postural Orthostatic Tachycardia Syndrome (POTS) Diary Study

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-012

Objective To explore the feasibility of daily diaries as an outcome measure in Postural Orthostatic Tachycardia Syndrome (POTS) patients in a clinical trial context.

Background POTS, the most common dysautonomia, predominantly affects young women and may occur with systemic autoimmune disease or recent infection. Symptom severity measured at a single time point may not accurately reflect clinical changes. There is currently no POTS-specific patient reported outcome measure. Patient diaries have been used to help track symptoms and compliance in other disorders, but their reliability and value in POTS has not been evaluated.

Design/Methods This secondary study was conducted during a randomized controlled clinical trial evaluating intravenous immunoglobulin (IVIG) compared to albumin infusions in patients with POTS. In addition to regular visits, participants completed a standardized daily symptom/activity diary. The daily diary entry included daily water intake, exercise type and duration, and Likert rating of overall POTS symptoms from 0 (no symptoms) to 10 (most severe). Completed diaries were collected at each study visit.

Results Daily diary completion was 96.8% during the first 15 weeks of the study (n = 27) and 97.8% for the entire 32 weeks (n = 21). Participants reported compliance with fluid intake recommendations (2 L per day) 75.8% of days during the first 15 study weeks, and 80.1% for the full 32 weeks. Overall, the diary study showed daily symptom severity correlated with primary outcome measures.

Conclusions Use of a daily symptom diary for POTS patients is feasible. A symptom and activity diary may not only provide additional clinical data but may also improve compliance with recommendations for daily fluid intake and exercise. Daily POTS diaries could be used effectively in future intervention trials or as an adjunct to standard practice.

Authors/Disclosures
Christian J. Hernandez-Zegada PRESENTER	Mr. Hernandez-Zegada has nothing to disclose.
Steven Vernino, MD, PhD, F�鶹��ýӳ�� (UT Southwestern Medical Center)	Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for lundbeck. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regeneron. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alterity. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Autonomic Neuroscience (Elsevier). The institution of Dr. Vernino has received research support from Takeda. The institution of Dr. Vernino has received research support from NIH/NHLBI. The institution of Dr. Vernino has received research support from Lundbeck. The institution of Dr. Vernino has received research support from Regeneron.
Steve Hopkins	Steve Hopkins has nothing to disclose.

�鶹��ýӳ��

�鶹��ýӳ��